# FDA details concerns with unapproved GLP-1 products

> FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.

- Evidence object: `story:fda-unapproved-glp1-concerns-record:v1`
- Evidence domain: Safety
- Date in source: 2026-05-31
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/
- JSON record: https://peptidescanner.com/evidence/v1/objects/fda-unapproved-glp1-concerns-record-v1.json
- Content SHA-256: `0e66f6d40ee2b1e58b41866285e2b35d1c790e32e7639986b9bc98ab1fb34b05`

## Claims and source pins

### Headline

FDA details concerns with unapproved GLP-1 products ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

### Summary

FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026. ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

### Paragraph 1

FDA's page distinguishes FDA-approved products from unapproved versions and compiles agency concerns, enforcement activity, reported quality problems, and adverse-event information dated May 31, 2026. ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

### Paragraph 2

This update attributes those statements to FDA and does not evaluate a product, pharmacy, treatment choice, or individual report. It also does not turn FDA's examples into a complete market survey. ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

## Sources

<a id="source-fda-unapproved-glp1-concerns-2026"></a>
- **FDA concerns with unapproved GLP-1 drugs used for weight loss** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) (`fda-unapproved-glp1-concerns-2026`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "FDA details concerns with unapproved GLP-1 products." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/objects/fda-unapproved-glp1-concerns-record-v1.json SHA-256: 0e66f6d40ee2b1e58b41866285e2b35d1c790e32e7639986b9bc98ab1fb34b05.